Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 945

1.

Novel Biomarkers Improves Prediction of 365-day Readmission after Pediatric Congenital Heart Surgery.

Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, Parikh CR, Pasquali SK, Brown JR.

Ann Thorac Surg. 2019 Jul 16. pii: S0003-4975(19)31035-5. doi: 10.1016/j.athoracsur.2019.05.070. [Epub ahead of print]

PMID:
31323208
2.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Jul 10. pii: blood.2019000490. doi: 10.1182/blood.2019000490. [Epub ahead of print]

PMID:
31292113
3.

Biomarkers improve prediction of 30-day unplanned readmission or mortality after paediatric congenital heart surgery.

Brown JR, Stabler ME, Parker DM, Vricella L, Pasquali S, Leyenaar JK, Bohm AR, MacKenzie T, Parikh C, Jacobs ML, Jacobs JP, Everett AD.

Cardiol Young. 2019 Jul 10:1-6. doi: 10.1017/S1047951119001471. [Epub ahead of print]

PMID:
31290383
4.

Healthcare spending in the State of Louisiana.

Kruger BP, Brown JR.

BMC Health Serv Res. 2019 Jul 9;19(1):471. doi: 10.1186/s12913-019-4275-y.

5.

Cardiac Biomarkers Predict Long-Term Survival After Cardiac Surgery.

Ramkumar N, Jacobs JP, Berman RB, Parker DM, MacKenzie TA, Likosky DS, DiScipio A, Malenka DJ, Brown JR.

Ann Thorac Surg. 2019 Jun 27. pii: S0003-4975(19)30893-8. doi: 10.1016/j.athoracsur.2019.04.123. [Epub ahead of print]

PMID:
31255614
6.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Jun 28. doi: 10.1158/1078-0432.CCR-18-3988. [Epub ahead of print]

PMID:
31253630
7.
8.

A multi-center analysis of readmission after cardiac surgery: Experience of The Northern New England Cardiovascular Disease Study Group.

Trooboff SW, Magnus PC, Ross CS, Chaisson K, Kramer RS, Helm RE, Desaulniers H, De La Rosa RC, Westbrook BM, Duquette D, Brown JR, Olmstead EM, Malenka DJ, Iribarne A.

J Card Surg. 2019 Jun 18. doi: 10.1111/jocs.14086. [Epub ahead of print]

PMID:
31212387
9.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.

Lancet Haematol. 2019 Jun 13. pii: S2352-3026(19)30104-8. doi: 10.1016/S2352-3026(19)30104-8. [Epub ahead of print]

PMID:
31208944
10.

Airway host-microbiome interactions in chronic obstructive pulmonary disease.

Wang Z, Maschera B, Lea S, Kolsum U, Michalovich D, Van Horn S, Traini C, Brown JR, Hessel EM, Singh D.

Respir Res. 2019 Jun 6;20(1):113. doi: 10.1186/s12931-019-1085-z.

11.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 Jun;570(7762):474-479. doi: 10.1038/s41586-019-1252-x. Epub 2019 May 29.

PMID:
31142838
12.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC.

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

13.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.

Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS.

Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533. [Epub ahead of print]

PMID:
31074316
14.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

15.

The opportunity cost of walking away in the spatial iterated prisoner's dilemma.

Premo LS, Brown JR.

Theor Popul Biol. 2019 Jun;127:40-48. doi: 10.1016/j.tpb.2019.03.004. Epub 2019 Apr 1.

PMID:
30946861
16.

Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.

Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, Thiessen-Philbrook H, Parikh CR, Brown JR.

J Card Surg. 2019 May;34(5):329-336. doi: 10.1111/jocs.14038. Epub 2019 Apr 3.

PMID:
30942505
17.

Claims-based surveillance for reintervention after endovascular aneurysm repair among non-Medicare patients.

Columbo JA, Sedrakyan A, Mao J, Hoel AW, Trooboff SW, Kang R, Brown JR, Goodney PP.

J Vasc Surg. 2019 Mar 25. pii: S0741-5214(19)30066-7. doi: 10.1016/j.jvs.2018.11.031. [Epub ahead of print]

PMID:
30922744
18.

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC.

Leuk Lymphoma. 2019 Mar 27:1-4. doi: 10.1080/10428194.2019.1594218. [Epub ahead of print] No abstract available.

PMID:
30916608
19.

Are Urinary Biomarkers Better Than Acute Kidney Injury Duration for Predicting Readmission?

Brown JR, Thiessen-Philbrook H, Goodrich CA, Bohm AR, Alam SS, Coca SG, McArthur E, Garg AX, Parikh CR.

Ann Thorac Surg. 2019 Jun;107(6):1699-1705. doi: 10.1016/j.athoracsur.2019.02.005. Epub 2019 Mar 14.

PMID:
30880140
20.

Prebiotic supplementation in frail older people affects specific gut microbiota taxa but not global diversity.

Tran TTT, Cousin FJ, Lynch DB, Menon R, Brulc J, Brown JR, O'Herlihy E, Butto LF, Power K, Jeffery IB, O'Connor EM, O'Toole PW.

Microbiome. 2019 Mar 13;7(1):39. doi: 10.1186/s40168-019-0654-1.

21.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
22.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

23.

Biomarkers for the prediction of cardiac readmission.

Parker DM, Brown JR.

Biomark Med. 2019 Feb;13(2):55-58. doi: 10.2217/bmm-2018-0381. Epub 2019 Jan 23. No abstract available.

24.

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ.

Blood. 2019 Feb 28;133(9):990-992. doi: 10.1182/blood-2018-06-857714. Epub 2018 Dec 28. No abstract available.

PMID:
30593446
25.

Inconsistent Inferences.

Ramkumar N, Brown JR.

Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e005235. doi: 10.1161/CIRCOUTCOMES.118.005235. No abstract available. Erratum in: Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e000053.

PMID:
30562076
26.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society.

Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

PMID:
30558987
27.

DUO delivers for duvelisib.

Brown JR.

Blood. 2018 Dec 6;132(23):2422-2424. doi: 10.1182/blood-2018-10-879650. No abstract available.

28.

Ibrutinib: searching for a partner drug.

Kater AP, Brown JR.

Lancet Oncol. 2019 Jan;20(1):3-5. doi: 10.1016/S1470-2045(18)30861-1. Epub 2018 Dec 3. No abstract available.

PMID:
30522966
29.

MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.

Improgo MR, Tesar B, Klitgaard JL, Magori-Cohen R, Yu L, Kasar S, Chaudhary D, Miao W, Fernandes SM, Hoang K, Westlin WF, Kim HT, Brown JR.

Br J Haematol. 2019 Mar;184(6):925-936. doi: 10.1111/bjh.15714. Epub 2018 Dec 9.

PMID:
30537114
30.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA.

Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

31.

Relapsed CLL: sequencing, combinations, and novel agents.

Brown JR.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):248-255. doi: 10.1182/asheducation-2018.1.248. Review.

PMID:
30504318
32.

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR, Bradner JE.

Cancer Cell. 2018 Dec 10;34(6):982-995.e7. doi: 10.1016/j.ccell.2018.11.001. Epub 2018 Nov 29.

PMID:
30503705
33.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

34.

sST2 as a novel biomarker for the prediction of in-hospital mortality after coronary artery bypass grafting.

Stabler ME, Rezaee ME, Parker DM, MacKenzie TA, Bohm AR, DiScipio AW, Malenka DJ, Brown JR.

Biomarkers. 2019 May;24(3):268-276. doi: 10.1080/1354750X.2018.1556338. Epub 2019 Jan 11.

PMID:
30512977
35.

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC.

J Clin Invest. 2019 Jan 2;129(1):122-136. doi: 10.1172/JCI99386. Epub 2018 Nov 19.

36.

Correction to: Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.

Bucciol G, Moens L, Payne K, Wollants E, Mekahli D, Levtchenko E, Vermeulen F, Tousseyn T, Gray P, Ma CS, Tangye SG, Van Ranst M, Brown JR, Breuer J, Meyts I.

J Clin Immunol. 2018 Nov;38(8):938-939. doi: 10.1007/s10875-018-0570-3.

PMID:
30430354
37.

Artificial intelligence in gastrointestinal endoscopy: The future is almost here.

Alagappan M, Brown JRG, Mori Y, Berzin TM.

World J Gastrointest Endosc. 2018 Oct 16;10(10):239-249. doi: 10.4253/wjge.v10.i10.239. Review.

38.

Elevated preoperative Galectin-3 is associated with acute kidney injury after cardiac surgery.

Wyler von Ballmoos M, Likosky DS, Rezaee M, Lobdell K, Alam S, Parker D, Owens S, Thiessen-Philbrook H, MacKenzie T, Brown JR.

BMC Nephrol. 2018 Oct 20;19(1):280. doi: 10.1186/s12882-018-1093-0.

39.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR.

Leuk Lymphoma. 2019 May;60(5):1312-1315. doi: 10.1080/10428194.2018.1519814. Epub 2018 Oct 15.

PMID:
30322319
40.

Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.

Bucciol G, Moens L, Payne K, Wollants E, Mekahli D, Levtchenko E, Vermeulen F, Tousseyn T, Gray P, Ma CS, Tangye SG, Van Ranst M, Brown JR, Breuer J, Meyts I.

J Clin Immunol. 2018 Oct;38(7):748-752. doi: 10.1007/s10875-018-0558-z. Epub 2018 Oct 11. No abstract available. Erratum in: J Clin Immunol. 2018 Nov;38(8):938-939.

PMID:
30311057
41.

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.

42.

Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.

Brown JR, Flemer B, Joyce SA, Zulquernain A, Sheehan D, Shanahan F, O'Toole PW.

BMC Gastroenterol. 2018 Aug 28;18(1):131. doi: 10.1186/s12876-018-0860-5.

43.

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.

Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Sarah Walker A, Thiebaut R, Klein N; CHAPAS-3 Trial Team .

J Infect Dis. 2019 Jan 1;219(1):89-100. doi: 10.1093/infdis/jiy495.

44.

Utility of Biomarkers to Improve Prediction of Readmission or Mortality After Cardiac Surgery.

Brown JR, Jacobs JP, Alam SS, Thiessen-Philbrook H, Everett A, Likosky DS, Lobdell K, Wyler von Ballmoos MC, Parker DM, Garg AX, Mackenzie T, Jacobs ML, Parikh CR.

Ann Thorac Surg. 2018 Nov;106(5):1294-1301. doi: 10.1016/j.athoracsur.2018.06.052. Epub 2018 Aug 4.

PMID:
30086283
45.

Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware.

Tam CS, Brown JR.

Leuk Lymphoma. 2018 Dec;59(12):2767-2768. doi: 10.1080/10428194.2018.1482546. Epub 2018 Jul 22. No abstract available.

PMID:
30032684
46.

Left Off the Route: A Qualitative Examination of Urban Bus Drivers Wanting to be Players in the Bully Prevention Solution.

Brown JR, Karikari I, Abraham S, Akakpo T.

J Interpers Violence. 2018 Jul 1:886260518787204. doi: 10.1177/0886260518787204. [Epub ahead of print]

PMID:
29991322
47.

High Viral Diversity and Mixed Infections in Cerebral Spinal Fluid From Cases of Varicella Zoster Virus Encephalitis.

Depledge DP, Cudini J, Kundu S, Atkinson C, Brown JR, Haque T, Houldcroft CJ, Koay ES, McGill F, Milne R, Whitfield T, Tang JW, Underhill G, Bergstrom T, Norberg P, Goldstein R, Solomon T, Breuer J.

J Infect Dis. 2018 Oct 5;218(10):1592-1601. doi: 10.1093/infdis/jiy358.

48.

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery.

Polineni S, Parker DM, Alam SS, Thiessen-Philbrook H, McArthur E, DiScipio AW, Malenka DJ, Parikh CR, Garg AX, Brown JR.

J Am Heart Assoc. 2018 Jul 7;7(14). pii: e008371. doi: 10.1161/JAHA.117.008371.

49.

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?

Brown JR.

Haematologica. 2018 Jul;103(7):1096-1098. doi: 10.3324/haematol.2018.196014. No abstract available.

50.

Use of Whole-Genome Sequencing of Adenovirus in Immunocompromised Pediatric Patients to Identify Nosocomial Transmission and Mixed-Genotype Infection.

Houldcroft CJ, Roy S, Morfopoulou S, Margetts BK, Depledge DP, Cudini J, Shah D, Brown JR, Romero EY, Williams R, Cloutman-Green E, Rao K, Standing JF, Hartley JC, Breuer J.

J Infect Dis. 2018 Sep 8;218(8):1261-1271. doi: 10.1093/infdis/jiy323.

PMID:
29917114

Supplemental Content

Loading ...
Support Center